Previous 10 | Next 10 |
MENLO PARK, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the...
2024-05-20 02:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-02 17:30:02 ET Truist Financial analyst issues BUY recommendation for CORT on May 2, 2024 04:01PM ET. The previous analyst recommendation was Buy. CORT was trading at $25.06 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ...
2024-05-01 23:42:02 ET Corcept Therapeutics Incorporated (CORT) Q1 2024 Earnings Conference Call May 1, 2024 17:00 ET Company Participants Atabak Mokari - Chief Financial Officer Charlie Robb - Chief Business Officer Joe Belanoff - Chief Executive Officer Wil...
2024-05-01 16:52:34 ET More on Corcept Therapeutics Corcept Therapeutics: Key Catalysts Ahead Corcept Therapeutics Incorporated (CORT) Q4 2023 Earnings Call Transcript Corcept Therapeutics Q1 2024 Earnings Preview Corcept falls after phase 3 results on Cushin...
Enact Holdings Inc. (ACT) is expected to report $0.99 for Q1 2024 FormFactor Inc. (FORM) is expected to report $0.09 for Q1 2024 SAAB AB - Class B (SAABF) is expected to report for quarter end 2024-03-31 Lumos Pharma Inc. (LUMO) is expected to report $-1.21 for Q1 2024 Axis Capita...
2024-04-30 17:20:27 ET More on Corcept Therapeutics Corcept Therapeutics: Key Catalysts Ahead Corcept Therapeutics Incorporated (CORT) Q4 2023 Earnings Call Transcript Corcept falls after phase 3 results on Cushing's candidate doesn't include some data Corcep...
MENLO PARK, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of th...
2024-04-22 11:22:23 ET More on Corcept Therapeutics Corcept Therapeutics: Key Catalysts Ahead Corcept Therapeutics Incorporated (CORT) Q4 2023 Earnings Call Transcript Corcept Therapeutics Q4 2023 Earnings Preview Seeking Alpha’s Quant Rating on Corcep...
A look at the top 10 most actives in the United States Moolec Science SA (MLEC) rose 85.7% to $2.6 on volume of 50,077,650 shares SuperCom Ltd. (SPCB) rose 46.0% to $0.3212 on volume of 37,315,721 shares AGBA Group Holding Limited (AGBA) rose 35.2% to $1.69 on volume of 26,672,582 shares ...
News, Short Squeeze, Breakout and More Instantly...
Corcept Therapeutics Incorporated Company Name:
CORT Stock Symbol:
NASDAQ Market:
Corcept Therapeutics Incorporated Website:
Results from the CATALYST clinical trial were presented at the American Diabetes Association’s 84 th Scientific Sessions at a featured plenary session titled: “Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes” With 1,055 patients enro...
2024-06-12 10:00:07 ET Edward Nash from Canaccord Genuity issued a price target of $38.00 for CORT on 2024-06-12 07:45:00. The adjusted price target was set to $38.00. At the time of the announcement, CORT was trading at $32.79. The overall price target consensus is at $...